XORTX Therapeutics

XRTX · TSX

$0.9201−$0.0487 (−5.03%)TodayMarket closed · Oct 23, 6:56 PM ET

Prev close $0.9688

Latest news

NewsOct 20, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsOct 9, 2:50 AM ETMohd Haider
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
Press releaseOct 8, 4:00 PM ETGlobe Newswire
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
NewsSep 18, 8:08 AM ET
XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program
Press releaseSep 18, 8:05 AM ETGlobe Newswire
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
NewsSep 11, 2:37 AM ETMohd Haider
XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know
Press releaseSep 10, 4:05 PM ETGlobe Newswire
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
Press releaseSep 8, 6:15 PM ETGlobe Newswire
XORTX Re-Engages Investor Relations Program
NewsAug 28, 7:19 AM ET
XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency
Press releaseAug 28, 7:00 AM ETGlobe Newswire
XORTX Announces Termination and Postponement of Investor Relations Program
NewsAug 26, 5:07 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseJul 31, 5:00 PM ETGlobe Newswire
XORTX Announces Director Resignation
Press releaseJul 29, 7:00 AM ETGlobe Newswire
XORTX Appoints New Director
Press releaseJun 15, 7:00 AM ETGlobe Newswire
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
Press releaseJun 12, 5:00 PM ETGlobe Newswire
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
NewsMay 29, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseMay 19, 7:00 AM ETGlobe Newswire
XORTX Announces Closing of US$5 Million Public Offering
NewsMay 15, 1:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseMay 14, 7:00 AM ETGlobe Newswire
XORTX Announces US$5 Million Public Offering
NewsMay 11, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsApr 1, 1:02 PM ET
XORTX Therapeutics Announces 1-For-5 Share Consolidation, Effective April 6, 2026
Press releaseApr 1, 1:00 PM ETGlobe Newswire
XORTX Confirms Effective Date of Share Consolidation
NewsMar 27, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsMar 26, 4:42 PM ET
XORTX Therapeutics Delays 1-for-5 Share Consolidation To April 6, Pending Approvals
Press releaseMar 26, 4:32 PM ETGlobe Newswire
XORTX Announces Change of Effective Date of Share Consolidation
NewsMar 24, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 24, 5:00 PM ETGlobe Newswire
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
Press releaseMar 18, 7:00 AM ETGlobe Newswire
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
Press releaseMar 13, 7:00 AM ETGlobe Newswire
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation
Press releaseMar 5, 7:00 AM ETGlobe Newswire
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
NewsMar 4, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsFeb 27, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsFeb 5, 4:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseFeb 4, 6:00 PM ETGlobe Newswire
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
Press releaseDec 31, 6:15 PM ETGlobe Newswire
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
NewsNov 3, 5:09 AM ETAvi Kapoor
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Press releaseOct 29, 7:00 AM ETGlobe Newswire
XORTX Announces Closing of US$1.1 Million Registered Direct Offering
Press releaseOct 21, 8:00 AM ETGlobe Newswire
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
Press releaseOct 20, 8:34 PM ETGlobe Newswire
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
Press releaseOct 20, 6:45 PM ETGlobe Newswire
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Press releaseOct 17, 7:00 AM ETGlobe Newswire
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Tuesday's After-Market Session

XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why

XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout

XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

XORTX Re-Engages Investor Relations Program

XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency

XORTX Announces Termination and Postponement of Investor Relations Program

12 Health Care Stocks Moving In Wednesday's After-Market Session

XORTX Announces Director Resignation

XORTX Appoints New Director

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

12 Health Care Stocks Moving In Friday's After-Market Session

XORTX Announces Closing of US$5 Million Public Offering

12 Health Care Stocks Moving In Friday's Intraday Session

XORTX Announces US$5 Million Public Offering

12 Health Care Stocks Moving In Monday's Pre-Market Session

XORTX Therapeutics Announces 1-For-5 Share Consolidation, Effective April 6, 2026

XORTX Confirms Effective Date of Share Consolidation

12 Health Care Stocks Moving In Friday's Intraday Session

XORTX Therapeutics Delays 1-for-5 Share Consolidation To April 6, Pending Approvals

XORTX Announces Change of Effective Date of Share Consolidation

12 Health Care Stocks Moving In Tuesday's After-Market Session

XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket

XORTX Announces Closing of US$1.1 Million Registered Direct Offering

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems